...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical Medicine Research >Effects of Repaglinide Versus Glimepiride on 1,5-Anhydroglucutol and Glycated Hemoglobin Levels in Japanese Patients With Type 2 Diabetes
【24h】

Effects of Repaglinide Versus Glimepiride on 1,5-Anhydroglucutol and Glycated Hemoglobin Levels in Japanese Patients With Type 2 Diabetes

机译：瑞格列奈与格列美脲对日本2型糖尿病患者1,5-脱水谷氨醇和糖化血红蛋白水平的影响

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Postprandial hyperglycemia is a well-known risk factor for cardiovascular disease. We prospectively examined the effects of repaglinide on postprandial hyperglycemia in patients with type 2 diabetes. Methods: During this 24-week, single-arm, prospective study, we enrolled 10 patients with type 2 diabetes who were previously being administered glimepiride (0.5 or 1 mg/day) and switched it with repaglinide (0.75 or 1.5 mg/day). Changes in their metabolic parameters were evaluated at the end of the study period. Results: After replacing glimepiride with repaglinide, increases were observed in 1,5-anhydroglucitol levels (baseline, 5.46 ± 1.96 versus 24 weeks, 9.15 ± 4.48 μg/mL, P = 0.004) but not in glycated hemoglobin levels (baseline, 7.7 ± 0.5 versus 24 weeks, 7.4 ± 0.6%, P = 0.100). Body weight remained unchanged. Conclusion: Compared with glimepiride, repaglinide improved 1,5-anhydroglucitol levels but had no effect on glycated hemoglobin. This suggests that repaglinide is a useful option for treating postprandial hyperglycemia.
机译：背景：餐后高血糖是心血管疾病的众所周知的危险因素。我们前瞻性地研究了瑞格列奈对2型糖尿病患者餐后高血糖的影响。方法：在这项为期24周的单臂前瞻性研究中，我们招募了10名先前曾接受格列美脲（0.5或1毫克/天）的2型糖尿病患者，并换用瑞格列奈（0.75或1.5毫克/天）。 。在研究期结束时评估其代谢参数的变化。结果：用瑞格列奈替代格列美脲后，观察到1,5-脱水葡萄糖醇水平升高（基线，5.46±1.96比24周，9.15±4.48μg/ mL，P = 0.004），但糖化血红蛋白水平未升高（基线，7.7± 0.5对比24周，7.4±0.6％，P = 0.100）。体重保持不变。结论：与格列美脲相比，瑞格列奈可改善1,5-脱水葡萄糖醇水平，但对糖化血红蛋白无影响。这表明瑞格列奈是治疗餐后高血糖的有用选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号